BACKGROUND: We describe data on 10,472 renal biopsies gathered by the Czech Registry of Renal Biopsies over a period of 18 years. METHODS: We assessed the main demographic, clinical and histological data of individuals who underwent renal biopsies of native kidneys in 31 centers in the Czech Republic (population 10.3 million) during the period 1994-2011. RESULTS: We evaluated 10,472 renal biopsies: males 57.8%, children (≤15 years) 13.6%, elderly (>60 years) 19.1%. The most frequent biopsy-proven diseases were primary (55.7%) and secondary (29.1%) glomerulonephritides (GN). Tubulointerstitial nephritis (TIN) was observed in 3.4 % and vascular diseases in 4.1%. The samples were non-diagnostic in 4.2%. Among primary GN the most frequent diagnoses were IgA nephropathy (IgAN) (37.4%), membranous GN (MGN) (13%) and focal segmental glomerulosclerosis (FSGS) (12.6%). Among secondary GN, systemic lupus erythematosus (SLE) represented 23.2%, hereditary diseases 19.8% and necrotizing vasculitis (NV) 19.4%. Among adults, mild renal insufficiency [serum creatinine (SCr) 111-200 μmol/l] was present in 24.7%, advanced renal insufficiency (SCr 201-400 μmol/l) in 15.3, and 12.3% of patients had SCr > 400 μmol/l. The most common diseases in patients with nephrotic proteinuria were minimal change disease (MCD) (39.7%) among children, IgAN (26.2%) in adults aged 16-60 years and amyloidosis (42.7%) among the elderly. The mean annual incidence (per million population) was: primary GN 30.9, secondary GN 18.1, IgAN 11.6, MGN 4.0, SLE 4.0, FSGS 3.9, MCD 3.4, NV 3.2, diabetic nephropathy 2.3, thin basement membrane glomerulopathy 2.0, mesangioproliferative GN 1.9, and TIN 1.9. Ultrasound needle guidance was used in 66.8%. The frequency of serious complications (symptomatic hematoma, gross hematuria, blood transfusion) was approximately 3.2%. CONCLUSIONS: This report provides representative population-based data on native biopsy-proven renal diseases in the Czech Republic. Over the 18 years of nationwide biopsy survey, we noted an increase of the mean age of renal biopsy cases, an increasing proportion of elderly, and a cardinal change in biopsy technique towards ultrasonography needle guidance.

• MeSH
• Amyloidosis pathology   MeSH
• Renal Insufficiency, Chronic pathology   MeSH
• Nephritis, Hereditary pathology   MeSH
• Diabetic Nephropathies epidemiology   pathology   MeSH
• Child MeSH
• Adult MeSH
• Glomerulonephritis epidemiology   pathology   MeSH
• Incidence MeSH
• Infant MeSH
• Kidney pathology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Nephrosis, Lipoid epidemiology   pathology   MeSH
• Adolescent MeSH
• Young Adult MeSH
• Necrosis epidemiology   etiology   pathology   MeSH
• Kidney Diseases epidemiology   pathology   MeSH
• Child, Preschool MeSH
• Registries MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Image-Guided Biopsy adverse effects   MeSH
• Vasculitis complications   epidemiology   pathology   MeSH
• Check Tag
• Child MeSH
• Adult MeSH
• Infant MeSH
• Middle Aged MeSH
• Humans MeSH
• Adolescent MeSH
• Young Adult MeSH
• Male MeSH
• Child, Preschool MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Geographicals
• Czech Republic epidemiology   MeSH

Renal amyloid involvement results, especially, from AL (primary) or AA (secondary) amyloidosis. The extent of amyloid tissue deposits in the kidneys and the clinical course of amyloidosis not only depend on the type of basic process but also reflect the time of diagnosis and the ability to affect the underlying disease. We analyzed laboratory and clinical data from patients with bioptically proven renal amyloidosis. Renal amyloidosis was found in 99 patients (4.65%) from an overall number of 2,128 renal biopsies (RB) performed in our department during a period of 11 years (from 1995 to 2006). AA amyloidosis was diagnosed in 46 patients. Nephrotic syndrome was diagnosed in 27 patients (59%) with AA amyloidosis; all these patients had different degrees of proteinuria. Impaired renal function was discovered in 24 patients (52%); in three of these patients (6.5%) we had to start renal replacement therapy. Patients were treated with corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biological therapy in various regimens. Nine patients (19.5%) died during the one-year follow-up period; complications such as sepsis and cardiac failure were the leading causes of death. Median survival in the AA group was 54 months. Although for approximately half of patients different treatment regimens can lead to a partial remission or disease stabilization, the prognosis of patients with amyloidosis could be regarded as unsatisfactory.

• MeSH
• Amyloid metabolism   MeSH
• Amyloidosis diagnosis   epidemiology   MeSH
• Survival Analysis MeSH
• Antirheumatic Agents therapeutic use   MeSH
• Kidney Failure, Chronic diagnosis   epidemiology   MeSH
• Adult MeSH
• Risk Assessment MeSH
• Immunohistochemistry MeSH
• Incidence MeSH
• Biopsy, Needle MeSH
• Cohort Studies MeSH
• Drug Therapy, Combination MeSH
• Middle Aged MeSH
• Humans MeSH
• Nephrology statistics & numerical data   MeSH
• Nephrotic Syndrome diagnosis   epidemiology   MeSH
• Kidney Diseases diagnosis   drug therapy   epidemiology   MeSH
• Statistics, Nonparametric MeSH
• Prednisolone therapeutic use   MeSH
• Prognosis MeSH
• Retrospective Studies MeSH
• Sex Distribution MeSH
• Aged MeSH
• Severity of Illness Index MeSH
• Age Distribution MeSH
• Kidney Function Tests MeSH
• Health Surveys MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH
• Geographicals
• Czech Republic epidemiology   MeSH
• Names of Substances
• Amyloid MeSH
• Antirheumatic Agents MeSH
• Prednisolone MeSH